Skip to main content
Features
Assistant
AI grounded in research
Search
Full-text citation search
Collections
Organize and monitor papers
All Features →
Integrations
MCP
Connect AI agents to Scite
API
Programmatic data access
Holdings
Full-text via your library
Zotero Plugin
Citation data in Zotero
Browser Extension
Citation badges anywhere
All Integrations →
Data
Rankings
Pricing
Log In
Start Free Trial
Features
Assistant
AI grounded in research
Search
Full-text citation search
Collections
Organize and monitor papers
All Features →
Integrations
MCP
Connect AI agents to Scite
API
Programmatic data access
Holdings
Full-text via your library
Zotero Plugin
Citation data in Zotero
Browser Extension
Citation badges anywhere
All Integrations →
Data
Rankings
Pricing
Log In
Start Free Trial
James Carmichael
Sign up to set email alerts
133
Publications
10,647
Citation Statements Received
704
Citation Statements Given
How they've been cited
16,414
308
10,302
37
How they cite others
2,447
20
676
8
Affiliations
Nottingham City Hospital
,
Churchill Hospital
Publications
Order By: Most citations
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from
BRCA
Mutation Carriers
Fong
1
,
Boss
2
,
Yap
3
et al.
2009
N Engl J Med
Abstract
Show
3,720
58
2,629
3
Get access via publisher
Add to collection
Cite
Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
Ledermann
1
,
Harter
2
,
Gourley
3
et al.
2012
N Engl J Med
Abstract
Show
1,922
54
1,486
2
Get access via publisher
Add to collection
Cite
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
Tutt
1
,
Robson
2
,
Garber
3
et al.
2010
The Lancet
1,736
22
1,161
5
Get access via publisher
Add to collection
Cite
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
Audeh
1
,
Carmichael
2
,
Penson
3
et al.
2010
The Lancet
2,241
28
946
2
Get access via publisher
Add to collection
Cite
Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study
Gelmon
1
,
Tischkowitz
2
,
MacKay
3
et al.
2011
The Lancet Oncology
1,121
33
777
4
Get access via publisher
Add to collection
Cite
Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in
BRCA
Carrier Ovarian Cancer Correlating With Platinum-Free Interval
Fong
1
,
Yap
2
,
Boss
3
et al.
2010
JCO
Abstract
Show
1,014
34
649
2
Get access via publisher
Add to collection
Cite
Topotecan Versus Cyclophosphamide, Doxorubicin, and Vincristine for the Treatment of Recurrent Small-Cell Lung Cancer
von Pawel
1
,
Schiller
2
,
Shepherd
3
et al.
1999
JCO
Abstract
Show
939
15
563
5
Get access via publisher
Add to collection
Cite
Phase II, Open-Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of Olaparib, a Poly (ADP-Ribose) Polymerase Inhibitor, and Pegylated Liposomal Doxorubicin in Patients With
BRCA1
or
BRCA2
Mutations and Recurrent Ovarian Cancer
Kaye
1
,
Lubiński
2
,
Matulonis
3
et al.
2012
JCO
Abstract
Show
475
13
271
4
Get access via publisher
Add to collection
Cite
1
2
3